• Limpopo

Free Weekly Newsline Every Friday

SAHPRA CEO: No Blanket Prohibition on Section 21, Applications Considered on Merit

SAHPRA’s CEO, Dr Boitumelo Semete-Makokotlela says the regulator does not authorize retail sales of cannabis and will soon clarify the situation around Section 21 access. In the meantime, she says properly backed-up applications for cannabis prescriptions under Section 21 will be considered,

 In response to a question from Cannabiz Africa as to whether all medical cannabis applications under Section 21 of the Medicines Act had been halted, SAHPRA CEO Dr Boitumelo Semete-Makokotlela (pictured here), sent this response on 18 November 2026.

“Please note that we will issue a communication on this matter. Kindly note that;

  1. there is no blanket prohibition on submitting medicinal cannabis applications;
  2. Section 21 remains an exceptional, named-patient pathway and does not authorise retail or commercial supply;
  3. applications may be considered where the clinical need and product-specific evidence are adequately demonstrated”.

Meanwhile, SAHPRA’s Senior Manager, Market Control Mokgadi Daphne Fafudi, told participants in a webinar on 18 November 2026 that the entire Section 21 medical cannabis pathway has been tightened up and is being reviewed.

Speaking  at an online webinar organized by the Southern African Pharmaceutical Regulatory Affairs Association ( SAPAA – not to be confused with SAHPRA), Fafudi said that had been widespread abuse of Section 21 by people seeking access to cannabis for non-medical purposes.

Section 21 of the Medicines Act, which allows for doctors to prescribe a medicine for a treatment for which there is no registered alternative available.

“Section 21 has to be reviewed. There are products that are appearing in shopping malls and informal markets that claim to be authorized to sell Section 21 cannabis, but this is not the case” she said. “We will never issue permits for a scheduled medicine to be available for sale in shopping centres”.

“We will work with the police to have these shops put down” she  said. “A private retailer cannot sell medicine”.

Fafudi said that doctors and patients seeking Section 21 approval for genuine medical conditions could still get the go-ahead in the interim.

“With proper evidence-based submissions, such applications will still be considered” she said.

#

Share this post
The Cannabiz Africa Briefing

One weekly email. Everything moving in African cannabis.

"*" indicates required fields

Name*

Search news, companies, regulations

Start typing below to search Cannabiz Africa.